Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 10Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Blood Specimen Collection 22Surveys and Questionnaires 19Nivolumab 14Ipilimumab 12pembrolizumab 11Gene Expression Profiling 11Biopsy 10trametinib 9dabrafenib 8Flow Cytometry 8Specimen Handling 7Polymerase Chain Reaction 7Tomography, Optical Coherence 6Therapeutics 6Immunohistochemistry 6Imiquimod 6Amplified Fragment Length Polymorphism Analysis 6Watchful Waiting 5Psychiatric Rehabilitation 5Immunotherapy 5Data Collection 53-ingenyl angelate 5Mohs Surgery 4Microarray Analysis 4Interviews as Topic 4Immunoenzyme Techniques 4Drug Therapy 4Dermoscopy 4sonidegib 3encorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × denileukin diftitox × Dermatologic × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡